Previous Scientific Advisory Board members

Dr Doug Easton, Institute of Public Health, University of Cambridge, Cambridge

Dr Doug Easton is a Principal Research Fellow of Cancer Research UK and Director of the Cancer Research UK Genetic Epidemiology Unit, University of Cambridge. He was elected a Fellow of the Academy of Medical Sciences in 2002. A member of the National Institute for Clinical Excellence (NICE) guideline development group on familial breast cancer, he also sits on the steering committee of the Breast Cancer Information Core (BIC) and the Advisory Committee to the NIH Cancer Family Registry (CFRBCS).

His principal research interests are in genetic epidemiology of common diseases, especially cancer and his major research contributions have been in design and analysis of large-scale epidemiological studies, and in the development of original statistical methodology.

<h2>Dr Doug Easton, Institute of Public Health, University of Cambridge, Cambridge</h2><p>Dr Doug Easton is a Principal Research Fellow of Cancer Research UK and Director of the Cancer Research UK Genetic Epidemiology Unit, University of Cambridge. He was elected a Fellow of the Academy of Medical Sciences in 2002. A member of the National Institute for Clinical Excellence (NICE) guideline development group on familial breast cancer, he also sits on the steering committee of the Breast Cancer Information Core (BIC) and the Advisory Committee to the NIH Cancer Family Registry (CFRBCS).</p><p>His principal research interests are in genetic epidemiology of common diseases, especially cancer and his major research contributions have been in design and analysis of large-scale epidemiological studies, and in the development of original statistical methodology.</p>

Miss Zoë Winters, University of Bristol, Bristol

Miss Winters studied medicine and surgery at the University of The Witwatersrand, Johannesburg, South Africa and was subsequently awarded an Oxford Nuffield Medical Fellowship to do a PhD at the Institute of Molecular Medicine in Oxford. Following this she was appointed as a Consultant Senior Lecturer in Breast Surgery in the Department of Clinical Sciences at South Bristol, University of Bristol and was awarded the King James IV Professorship in 2001 from the Royal College of Surgeons of Edinburgh.

She collaborates with a research group investigating the interaction between tumour suppressor pathways inhibiting breast cancer growth and their interaction with growth factors that predict aggressive breast cancers. Understanding the mechanisms underlying these interactions will be important in strategising future breast cancer treatments.

<h2>Miss Zoë Winters, University of Bristol, Bristol</h2><p>Miss Winters studied medicine and surgery at the University of The Witwatersrand, Johannesburg, South Africa and was subsequently awarded an Oxford Nuffield Medical Fellowship to do a PhD at the Institute of Molecular Medicine in Oxford. Following this she was appointed as a Consultant Senior Lecturer in Breast Surgery in the Department of Clinical Sciences at South Bristol, University of Bristol and was awarded the King James IV Professorship in 2001 from the Royal College of Surgeons of Edinburgh.</p><p>She collaborates with a research group investigating the interaction between tumour suppressor pathways inhibiting breast cancer growth and their interaction with growth factors that predict aggressive breast cancers. Understanding the mechanisms underlying these interactions will be important in strategising future breast cancer treatments.</p>

Dr Penelope Hopwood, Christie Hospital NHS Trust, Manchester

Dr Hopwood is Consultant in Psychiatry and Psycho-Oncology at The Christie Hospital NHS Trust in Manchester and is widely involved in psychosocial research in Breast Cancer and Cancer Genetics.

She formerly worked as an academic psychiatrist in Oncology researching Quality of Life assessment, body image problems and psychological effects of advanced cancer. Recent projects included the psychological impact of a genetic risk of breast cancer and preventive surgery, and evaluation of cancer genetics service provision.

<h2>Dr Penelope Hopwood, Christie Hospital NHS Trust, Manchester</h2><p>Dr Hopwood is Consultant in Psychiatry and Psycho-Oncology at The Christie Hospital NHS Trust in Manchester and is widely involved in psychosocial research in Breast Cancer and Cancer Genetics.</p><p>She formerly worked as an academic psychiatrist in Oncology researching Quality of Life assessment, body image problems and psychological effects of advanced cancer. Recent projects included the psychological impact of a genetic risk of breast cancer and preventive surgery, and evaluation of cancer genetics service provision.</p>

Dr Peter Barrett-Lee, Velindre Hospital, Cardiff

Dr Peter Barrett-Lee, BSc MD FRCP FRCR, is Consultant Oncologist in the Breast Unit at Velindre Hospital, and Honorary Senior Lecturer (visiting) at the Welsh School of Pharmacy Tenovus Laboratories, having trained in oncology at the Royal Marsden and Middlesex Hospitals in London. He is the lead clinician in Cardiff responsible for non-surgical breast oncology, and was chairman of the Royal College of Radiologists COIN Specialty Working Group on breast cancer.

His main research interests are studies of genetic predisposition to breast cancer, and the development of biological predictors of treatment response in adjuvant therapy for primary breast cancer. He is Editor of the journal ‘CME Cancer medicine” and was assistant Editor of ‘Breast Cancer Abstracts’. He also shares, with his colleague Dr Paul Ellis, the role of lead Principal Investigator for the NCRI/CRUK Taxotere as Adjuvant Chemotherapy (TACT) for breast cancer trial, as well as being one of the CRUK grant holders.

<h2>Dr Peter Barrett-Lee, Velindre Hospital, Cardiff</h2><p>Dr Peter Barrett-Lee, BSc MD FRCP FRCR, is Consultant Oncologist in the Breast Unit at Velindre Hospital, and Honorary Senior Lecturer (visiting) at the Welsh School of Pharmacy Tenovus Laboratories, having trained in oncology at the Royal Marsden and Middlesex Hospitals in London. He is the lead clinician in Cardiff responsible for non-surgical breast oncology, and was chairman of the Royal College of Radiologists COIN Specialty Working Group on breast cancer.</p><p>His main research interests are studies of genetic predisposition to breast cancer, and the development of biological predictors of treatment response in adjuvant therapy for primary breast cancer. He is Editor of the journal ‘CME Cancer medicine” and was assistant Editor of ‘Breast Cancer Abstracts’. He also shares, with his colleague Dr Paul Ellis, the role of lead Principal Investigator for the NCRI/CRUK Taxotere as Adjuvant Chemotherapy (TACT) for breast cancer trial, as well as being one of the CRUK grant holders.</p>

Professor Diana Eccles, Southampton General Hospital

Professor Eccles is a Consultant in Clinical Genetics at Wessex Clinical Genetics Service, and an Honorary Senior Lecturer in the Cancer Genetics at the University of Southampton.

Main clinical interests are genetic predisposition to tumours (benign and malignant) genetic testing and management of high genetic risk families.

Main research interests are genetic predisposition to breast cancer and to colorectal cancer chemoprevention, early detection, new methodologies for molecular testing and genetic epidemiology.

<h2>Professor Diana Eccles, Southampton General Hospital</h2><p>Professor Eccles is a Consultant in Clinical Genetics at Wessex Clinical Genetics Service, and an Honorary Senior Lecturer in the Cancer Genetics at the University of Southampton.</p><p>Main clinical interests are genetic predisposition to tumours (benign and malignant) genetic testing and management of high genetic risk families.</p><p>Main research interests are genetic predisposition to breast cancer and to colorectal cancer chemoprevention, early detection, new methodologies for molecular testing and genetic epidemiology.</p>

Dr Robert Clarke, Christie Hospital NHS trust, Manchester

Dr Clarke studied Biology at the University of Sussex and the Université de Grenoble and obtained his PhD from the University of Manchester. Following post-doctoral training at the Christie Hospital, Manchester, he was appointed as a Senior Research Fellow in the University of Manchester Department of Medical Oncology.

His research group investigates breast epithelial biology. His specific interests are, firstly, to understand the tissue’s growth and differentiation from stem cells under the influence of ovarian hormones, and secondly, to learn how breast cancer risk factors affect the biology of the normal breast.

<h2>Dr Robert Clarke, Christie Hospital NHS trust, Manchester</h2><p>Dr Clarke studied Biology at the University of Sussex and the Université de Grenoble and obtained his PhD from the University of Manchester. Following post-doctoral training at the Christie Hospital, Manchester, he was appointed as a Senior Research Fellow in the University of Manchester Department of Medical Oncology.</p><p>His research group investigates breast epithelial biology. His specific interests are, firstly, to understand the tissue’s growth and differentiation from stem cells under the influence of ovarian hormones, and secondly, to learn how breast cancer risk factors affect the biology of the normal breast.</p>

Professor Andrew Hanby, St James's University Hospital, Leeds

Professor Andrew Hanby is Professor of Breast Pathology and consultant histopathologist at St James's University Hospital in Leeds. He has been involved in breast cancer research since 1989, including self driven indigenous research, extensive collaborative research and the IBIS-1 trial. His particular expertise is in tissue banking, issues related to consent and the production of tissue micro-arrays (TMAs). He maintains a diagnostic workload and is lead for the regional HER2 testing service.

Dr Emma Pennery, Breast Care Clinical Nurse Specialist, London

Emma Pennery worked as a Senior Clinical Nurse Specialist, Honorary Lecturer and Clinical Research Fellow at the Royal Marsden Hospital and the Institute of Cancer Research for eight years, having previously been a ward sister on units with surgical, chemotherapy and radiotherapy patients. A member of the RCN Breast Care Nursing Forum Steering Committee and the Department of Health Cancer Nursing Advisory Committee, Emma achieved an MSc in Advanced Clinical Practice in 1995 at Surrey University.

Her main interests include nursing support for breast cancer patients; advanced nursing practice issues & extended roles, and the needs of people after treatment for breast cancer has been completed.

<h2>Dr Emma Pennery, Breast Care Clinical Nurse Specialist, London</h2><p>Emma Pennery worked as a Senior Clinical Nurse Specialist, Honorary Lecturer and Clinical Research Fellow at the Royal Marsden Hospital and the Institute of Cancer Research for eight years, having previously been a ward sister on units with surgical, chemotherapy and radiotherapy patients. A member of the RCN Breast Care Nursing Forum Steering Committee and the Department of Health Cancer Nursing Advisory Committee, Emma achieved an MSc in Advanced Clinical Practice in 1995 at Surrey University.</p><p>Her main interests include nursing support for breast cancer patients; advanced nursing practice issues & extended roles, and the needs of people after treatment for breast cancer has been completed.</p>

Dr Joy Burchell, Guy's Hospital, London

Dr Joy Burchell is a Cancer Research UK Staff Scientist and Honorary Senior Lecturer in the Division of Oncology, Guy's, King's and St Thomas' School of Medicine, London. Joy has spent the last 19 years in breast cancer research, initially at the Imperial Cancer Research Fund at Lincoln's Inn Fields and now at the Cancer Research UK laboratories at Guy's Hospital. Her research focus is the molecular changes that occur in breast cancer, with a particular emphasis on changes in glycosylation and research into an immunotherapeutic approach to breast cancer treatment.

Dr Stephen Johnston

Dr Johnston is Consultant Medical Oncologist and Director of Clinical R&D at the Royal Marsden Hospital and Institute of Cancer Research in London. He specialises in the medical management of breast cancer, and one of his major interests is research into endocrine resistance and the development of novel endocrine and signal transduction inhibitor therapies. In addition to undertaking laboratory research into mechanisms of resistance with clinically derived material, Dr Johnston also is involved in the design and running of various clinical trials in breast cancer. He has published over 150 peer-reviewed papers related to breast cancer, and is Deputy Editor of the web-based journal Breast Cancer Research. He is past Chairman of the Breast Cancer Campaign’s Scientific Committee, and now a Trustee of the charity.

Professor Claire Lewis

Professor Claire Lewis and her group are dedicated to providing innovative and effective treatments for invasive carcinoma
of the breast and ovary. Professor Lewis and her team are currently developing: (I) new drugs to block crucial steps in the establishment, growth and spread of tumours, (II) novel, cell-based gene delivery systems to target the expression of genes encoding such therapeutic proteins to the heart of solid tumours, and (III) mathematical models to predict the clinical efficacy of these new therapeutic approaches.

Professor Ian Hart

Having gained his BVSc in 1972 and his Ph.D in the Department of Veterinary Medicine at Bristol in 1976, Professor Hart initially took a post-doctoral position and later a Staff Scientist position in the Frederick Cancer Centre.

He returned to become a Principal Scientist at the Imperial Cancer Research Fund in 1983. He was awarded the Professorship of the Richard Dimbleby Department of Cancer Research, St. Thomas's Hospital, London, in 1993.

Professor Hart, who is an FRCPath, was presented in May 2000 with the highest honour that a non-medically qualified person can receive from the Royal College of Physicians, an Honorary FRCP.

Professor Hart's main interests lie in the study of metastatic spread of cancer, the biology of melanoma and cancer gene therapy. He is past secretary and Chairman of the BACR,President of the BOA and Chairman of the Scientific Committee of AICR and a member of the MRC Clinician Scientist Training Panel among many outside interests.

<h2>Professor Ian Hart <br /><br /></h2><p>Having gained his BVSc in 1972 and his Ph.D in the Department of Veterinary Medicine at Bristol in 1976, Professor Hart initially took a post-doctoral position and later a Staff Scientist position in the Frederick Cancer Centre.</p><p>He returned to become a Principal Scientist at the Imperial Cancer Research Fund in 1983. He was awarded the Professorship of the Richard Dimbleby Department of Cancer Research, St. Thomas's Hospital, London, in 1993.</p><p>Professor Hart, who is an FRCPath, was presented in May 2000 with the highest honour that a non-medically qualified person can receive from the Royal College of Physicians, an Honorary FRCP.</p><p><br />Professor Hart's main interests lie in the study of metastatic spread of cancer, the biology of melanoma and cancer gene therapy. He is past secretary and Chairman of the BACR,President of the BOA and Chairman of the Scientific Committee of AICR and a member of the MRC Clinician Scientist Training Panel among many outside interests. </p>

Professor Bill Miller

Professor Miller's research is "translational" and centres on the endocrinology of the breast and its cancers.

His specific interests include the mechanisms by which tumours accumulate and synthesize steroid hormones, environmental oestrogens, evaluation of anti-hormonal agents, identification of early response and resistance to endocrine treatment and the processes by which tumours by-pass hormonal restraints.

Dr Chris Twelves, Beatson Institute of Cancer Research, Glasgow

Dr Twelves is Reader and honorary Consultantin Medical Oncology at the Cancer Research Campaign Department in Glasgow and hasbeen there for six years. He completed his training in the Breast Unit at Guy's Hospital, London.

His principle clinical interests are in colorectal cancer and breast cancer. Dr Twelves' research interests encompass drug development from the early pre-clinical testing of new agents, through their clinical evaluation and into their incorporation in standard clinical protocols.

He has published research papers in the areas of drug development, clinical trials in breast and colorectal cancer as well as studies of quality of life and issues relating to delivery of health care.

Professor Rosemary Walker, University of Leicester

Dr Walker is currently Head of department of Pathology at the University of Leicester and has recently been appointed Professor of Pathology there.

She is also Head of the Breast Cancer Research Unit at the University of Leicester. She is currently Lead Breast Pathologist at the University Hospitals of

Leicester NHS Trust and Lead Pathologist for Leicestershire Cancer Centre.

Professor Mitchell Dowsett, Ph.D.

Professor Mitchell Dowsett is Professor of Biochemical Endocrinology (1994) and was the Head of the Academic Department of Biochemistry at the Institute of Cancer Research and Royal Marsden NHS Trust (1990). He received his BSc. (Zoology) from Imperial College at London University and his Ph.D. from Chester Beatty Cancer Research Institute at London University.

Professor Dowsett is an active member of numerous cancer committees, a member of the Steering Committees of four chemoprevention trials, and Co-Chairman of the pathology sub-committee of the ATAC trial; the largest trial of adjuvant therapy conducted in breast cancer. He is Co-Chair of the Translational Research Committee of the HERA Trial and has recently become Chairman of the NTRAC Translational Research Committee that aims to markedly enhance the value of translational research in the UK’s national portfolio of phase III clinical trials in cancer. He is author of more than 350 published papers related to breast cancer.

Professor Dowsett’s research focuses exclusively on breast cancer and predominantly on hormonal aspects of the disease. He has been closely involved with the development of aromatase inhibitors over a period of 20 years. These drugs have been shown to have superior efficacy to tamoxifen. His lab has interests in biomarkers for the treatment and prevention of breast cancer.

Professor Adrian Harris, University of Oxford

Adrian L Harris is the Imperial Cancer Research Fund Professor of MedicalOncology at the University of Oxford and Directs the ICRF Molecular Oncology Laboratories at the Institute of Molecular Medicine. Trained in General Medicine at Liverpool University, he also did a BSc in biochemistry. Following further medical training, he completed a DPhil at Oxford University on DNA Repair and then was appointed Professor of Oncology at Newcastle-upon-Tyne. Since 1988 he has been Professor of Oncology at Oxford University. He runs the Medical Oncology Unit providing a service to the NHS patients, as well as having a major interest in phase I and phase II trials, particularly involving anti-angiogenesis therapy and drug resistance. Laboratory interests include the mechanisms of tumour angiogenesis in particular thymidine phosphorylase and the hypoxia signalling pathway. Another major aim of the unit is to try and translate the laboratory studies to the bedside. Beside his own group at the Institute of Molecular Medicine he is the Director of the Molecular Oncology Laboratories which have groups working on ovarian cancer, genetic instability, and the cell cycle. Clinically, most of his research work is on breast cancer.

Dr Julia Gee, Tenovus Centre for Cancer Research, Cardiff

Dr. Gee is a Senior Research Associate in the Welsh School of Pharmacy and Research Co ordinator for the Tenovus Centre for Cancer Research.

Her research investigates growth factor signalling pathways that promote resistance to antihormones or signal transduction inhibitors in order to design new treatment strategies and improve breast cancer patient outlook. Her studies principally examine clinical breast cancers (including material from key pharmacological trials) and human breast cancer cell lines, with her team being expert in the use of phospho-specific signalling antibodies. She also has considerable interest in exploiting novel genes revealed by microarray profiling as future therapeutic targets in antihormonal resistant breast cancer.

<strong>Dr Julia Gee, Tenovus Centre for Cancer Research, Cardiff<br /><br /></strong>Dr. Gee is a Senior Research Associate in the Welsh School of Pharmacy and Research Co ordinator for the Tenovus Centre for Cancer Research.<br /><br />Her research investigates growth factor signalling pathways that promote resistance to antihormones or signal transduction inhibitors in order to design new treatment strategies and improve breast cancer patient outlook. Her studies principally examine clinical breast cancers (including material from key pharmacological trials) and human breast cancer cell lines, with her team being expert in the use of phospho-specific signalling antibodies. She also has considerable interest in exploiting novel genes revealed by microarray profiling as future therapeutic targets in antihormonal resistant breast cancer.

Professor Alastair Thompson, Ninewells Teaching Hospital, University of Dundee

Professor Alastair Thompson is Professor of Surgical Oncology at the University of Dundee and formerly King James IV Professor of Surgery, Royal College of Surgeons of Edinburgh. His specialist interests include the molecular biology of breast cancer and translating laboratory advances into improvements in clinical care for patients with breast cancer. Since 2002 he has been Executive Director of the Breast Cancer Research Centre based in Dundee.

<p><strong>Professor Alastair Thompson, Ninewells Teaching Hospital, University of Dundee<br /><br /></strong>Professor Alastair Thompson is Professor of Surgical Oncology at the University of Dundee and formerly King James IV Professor of Surgery, Royal College of Surgeons of Edinburgh. His specialist interests include the molecular biology of breast cancer and translating laboratory advances into improvements in clinical care for patients with breast cancer. Since 2002 he has been Executive Director of the Breast Cancer Research Centre based in Dundee. </p>

Dr Ruth Warren, Addenbrookes Hospital, Cambridge

Ruth Warren has been Consultant Radiologist at Addenbrooke's Hospital Cambridge and Associate Lecturer in the University of Cambridge since 1996. In 1987 she set up the first of the breast screening services of the new UK NHSBSP. She was Quality Assurance Director for Breast Screening for Eastern Region from 1998-2002.

Her research concentrates on the effectiveness of breast screening including participation in some of the major UK trials. Her work now concentrates on effectiveness of screening women at high risk, and this includes the role of study radiologist to the UK MRI breast screening study (MARIBS). Recent research has focused on mammographic density and its role in predicting and monitoring risk. She has had collaborations with psychologists, health economists, epidemiologists, and computer engineers in vision science and health grid projects.

<h2>Dr Ruth Warren, Addenbrookes Hospital, Cambridge</h2><p>Ruth Warren has been Consultant Radiologist at Addenbrooke's Hospital Cambridge and Associate Lecturer in the University of Cambridge since 1996. In 1987 she set up the first of the breast screening services of the new UK NHSBSP. She was Quality Assurance Director for Breast Screening for Eastern Region from 1998-2002.</p><p>Her research concentrates on the effectiveness of breast screening including participation in some of the major UK trials. Her work now concentrates on effectiveness of screening women at high risk, and this includes the role of study radiologist to the UK MRI breast screening study (MARIBS). Recent research has focused on mammographic density and its role in predicting and monitoring risk. She has had collaborations with psychologists, health economists, epidemiologists, and computer engineers in vision science and health grid projects.</p>

Professor George Davey Smith

George Davey Smith is Professor of Clinical Epidemiology at the University of Bristol, a visiting Professor at the London School of Hygiene and Tropical Medicine and Honorary Professor at the University of Glasgow. His main research interest relates to how socially patterned exposures acting over the entire life-course shape the health distribution between individuals, between populations and also influence long-term trends in health. In addition, George works on genetic epidemiology, sexually transmitted disease / HIV infection prevention activities in India and Nicaragua and on methodological issues in epidemiology. He is co-editor (with Shah Ebrahim) of the International Journal of Epidemiology.

The web address is: http://www.epi.bris.ac.uk/staff/gdaveysmith/gdaveysmith.htm

<p><strong>Professor George Davey Smith</strong></p><p>George Davey Smith is Professor of Clinical Epidemiology at the University of Bristol, a visiting Professor at the London School of Hygiene and Tropical Medicine and Honorary Professor at the University of Glasgow. His main research interest relates to how socially patterned exposures acting over the entire life-course shape the health distribution between individuals, between populations and also influence long-term trends in health. In addition, George works on genetic epidemiology, sexually transmitted disease / HIV infection prevention activities in India and Nicaragua and on methodological issues in epidemiology. He is co-editor (with Shah Ebrahim) of the International Journal of Epidemiology.</p><p>The web address is: <a href="http://www.epi.bris.ac.uk/staff/gdaveysmith/gdaveysmith.htm">http://www.epi.bris.ac.uk/staff/gdaveysmith/gdaveysmith.htm</a></p>

Dr Andrew Wardley

Dr Wardley is a Consultant Medical Oncologist and Co-Chair of the Breast Disease Orientated Group at Christie Hospital, Manchester. He is Clinical Research Lead for the Manchester Breast Centre and the Greater Manchester and Cheshire Breast Cancer Studies Group. In addition, Dr Wardley is a member of the National Cancer Research Institute Breast Cancer Studies Group, the Breast International Group, the Protocol Committee for the European Organisation for Research and Treatment of Cancer Breast Study Group and International Cancer Collaborative Group Steering Committee and the Association of Cancer Physicians Executive Committee.

A graduate of Manchester University, Dr Wardley plays an active role in the education of Specialist Trainees, medical students, nurses, pharmacists and allied professionals. He organised the 2005 ACP Summer School and lectured at the fifth European School of Oncology Masterclass in Clinical Oncology. Dr Wardley is currently involved in development of novel areas for breast cancer research in Manchester in collaboration with international groups. He has presented at both national and international conferences and published articles in journals such as The New England Journal of Medicine, The Journal of Clinical Oncology and The British Journal of Cancer. He is also Medical Oncology Specialty Sub-Editor for The Breast.

<p><strong>Dr Andrew Wardley<br /></strong><br />Dr Wardley is a Consultant Medical Oncologist and Co-Chair of the Breast Disease Orientated Group at Christie Hospital, Manchester. He is Clinical Research Lead for the Manchester Breast Centre and the Greater Manchester and Cheshire Breast Cancer Studies Group. In addition, Dr Wardley is a member of the National Cancer Research Institute Breast Cancer Studies Group, the Breast International Group, the Protocol Committee for the European Organisation for Research and Treatment of Cancer Breast Study Group and International Cancer Collaborative Group Steering Committee and the Association of Cancer Physicians Executive Committee. <br /><br />A graduate of Manchester University, Dr Wardley plays an active role in the education of Specialist Trainees, medical students, nurses, pharmacists and allied professionals. He organised the 2005 ACP Summer School and lectured at the fifth European School of Oncology Masterclass in Clinical Oncology. Dr Wardley is currently involved in development of novel areas for breast cancer research in Manchester in collaboration with international groups. He has presented at both national and international conferences and published articles in journals such as <em>The New England Journal of Medicine</em>, <em>The Journal of Clinical Oncology</em> and <em>The British Journal of Cancer</em>. He is also Medical Oncology Specialty Sub-Editor for The <em>Breast</em>.</p>

Professor Jim Metcalfe, University of Cambridge

Professor Jim Metcalfe obtained his PhD at the University of Cambridge and is currently Deputy Head/ Director of Research and Development at the Department of Biochemistry at The University of Cambridge.

<strong>Professor Jim Metcalfe, University of Cambridge</strong><br /><br />Professor Jim Metcalfe obtained his PhD at the University of Cambridge and is currently Deputy Head/ Director of Research and Development at the Department of Biochemistry at The University of Cambridge.

Dr Simon Langdon, Cancer Research Centre, Edinburgh

Dr Simon Langdon is a Cancer Research UK scientist and Honorary Senior Lecturer at the University of Edinburgh Cancer Research Centre based at the Western General Hospital. His research interests include investigation of the mechanisms of oestrogen sensitivity and resistance of breast cancer and use of growth factor signalling inhibitors as therapeutics.

Professor Louise Jones, St Bartholomew's Hospital

Professor Louise Jones gained a first class honours degree in Pathology from Leicester University in 1985, she went on to qualify as a medical doctor and subsequently achieved her PhD in 1999 at the Breast Cancer Research Unit at Leicester. She is currently a professor for Breast Pathology at Bart's Hospital.

<strong>Professor Louise Jones, St Bartholomew's Hospital</strong><br /><br />Professor Louise Jones gained a first class honours degree in Pathology from Leicester University in 1985, she went on to qualify as a medical doctor and subsequently achieved her PhD in 1999 at the Breast Cancer Research Unit at Leicester. She is currently a professor for Breast Pathology at Bart's Hospital.

Professor Paul Harkin BSc PhD

Paul Harkin is Professor of Molecular Oncology at the Centre for Cancer Research and Cell Biology, Queen’s University, Belfast. He is also President and MD of Almac Diagnostics, a biotech company now part of the Almac Group. Prior to this he had been a Research Fellow in Medicine at Harvard Medical School and the Massachusetts General Hospital where he focused on the functional characterisation of the BRCA1 tumour suppressor gene, which is mutated in the germline of women with a genetic predisposition to breast and ovarian cancer.

His academic work now utilises a range of high throughput genomic-based technologies to define the role played by BRCA1 in transcriptional regulation and as a predictor of response to chemotherapy.

<p><strong>Professor Paul Harkin BSc PhD</strong></p><p>Paul Harkin is Professor of Molecular Oncology at the Centre for Cancer Research and Cell Biology, Queen’s University, Belfast. He is also President and MD of Almac Diagnostics, a biotech company now part of the Almac Group. Prior to this he had been a Research Fellow in Medicine at Harvard Medical School and the Massachusetts General Hospital where he focused on the functional characterisation of the BRCA1 tumour suppressor gene, which is mutated in the germline of women with a genetic predisposition to breast and ovarian cancer. </p><p>His academic work now utilises a range of high throughput genomic-based technologies to define the role played by BRCA1 in transcriptional regulation and as a predictor of response to chemotherapy.</p>

Dr Fedor Berditchivski

Fedor Berditchivski graduated from the Moscow State University in Russia where he studied virology. He obtained his PhD in molecular biology from the Engelhardt Institute of Molecular Biology of Russian Academy of Sciences. He undertook post-doctoral training in the laboratory of Professor Joyce Taylor-Papadimitriou at the Imperial Cancer Research Fund in London, followed by training in the laboratory of Professor Martin Hemler at the Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. He was appointed as a Lecturer, subsequently, as a Senior Research Fellow, at the Cancer Research UK Institute for Cancer Studies, University of Birmingham. Fedor also serves on the AICR Scientific Advisory panel.

His research interests are focused on adhesion-dependent signalling pathways related to migration and invasion of breast cancer cells.

<p><strong>Dr Fedor Berditchivski</strong> </p><p>Fedor Berditchivski graduated from the Moscow State University in Russia where he studied virology. He obtained his PhD in molecular biology from the Engelhardt Institute of Molecular Biology of Russian Academy of Sciences. He undertook post-doctoral training in the laboratory of Professor Joyce Taylor-Papadimitriou at the Imperial Cancer Research Fund in London, followed by training in the laboratory of Professor Martin Hemler at the Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. He was appointed as a Lecturer, subsequently, as a Senior Research Fellow, at the Cancer Research UK Institute for Cancer Studies, University of Birmingham. Fedor also serves on the AICR Scientific Advisory panel.</p><p>His research interests are focused on adhesion-dependent signalling pathways related to migration and invasion of breast cancer cells.</p>